APO
Apollo Global Management, Inc.
APO lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
APO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| N/A | |
| N/A |
APO's revenue is currently stable, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like APO.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
APO PE Valuation
APO has no meaningful PE right now: it lost money over the past year.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
APO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for APO, with profitability holding steady.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
APO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.14 | — |
| Q3 2026 | -$1.81 | -126% |
| Q2 2026 | $2.75 | -49% |
| Q1 2026 | $1.59 | -72% |
| Q4 2025 | $5.54 | -24% |
| Q3 2025 | $6.86 | -27% |
| Q2 2025 | $5.37 | -42% |
| Q1 2025 | $5.73 | -36% |
| Q4 2024 | $7.33 | -11% |
APO has swung to a loss: it lost $1.81 per share over the past year, after a profit the year before.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has the edge over APO on earnings, with more consistent year-over-year improvement.
APO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | -52% |
| Q2 2026 | $11.2B | +64% |
| Q1 2026 | $5.1B | -8.8% |
| Q4 2025 | $9.9B | +87% |
| Q3 2025 | $9.8B | +26% |
| Q2 2025 | $6.8B | +13% |
| Q1 2025 | $5.5B | -21% |
| Q4 2024 | $5.3B | -52% |
APO's revenue is growing: $4.7B last quarter, down 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -31% | -60 points |
| Q2 2026 | 22% | +9.9 points |
| Q1 2026 | 5.6% | -16 points |
| Q4 2025 | 18% | -15 points |
| Q3 2025 | 30% | +2.7 points |
| Q2 2025 | 12% | -12 points |
| Q1 2025 | 21% | -9.8 points |
| Q4 2024 | 33% | +15 points |
APO has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over APO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
APO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $136M | -55% |
| Q2 2026 | $2.9B | +128% |
| Q1 2026 | $1.6B | +60% |
| Q4 2025 | $4.7B | +$4.7B |
| Q3 2025 | $303M | -84% |
| Q2 2025 | $1.3B | -5.3% |
| Q1 2025 | $1B | +1346% |
| Q4 2024 | -$4M | -100% |
APO has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
APO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -7.6M shares |
| 1 year | -0.9% | -5.2M shares |
| 3 years | +4.1% | +23.8M shares |
| 5 years | +152% | +363M shares |
| Available history | +170% | +380M shares |
APO has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $118M |
| Q2 2026 | $97M |
| Q1 2026 | $632M |
| Q4 2025 | $240M |
| Q3 2025 | $340M |
| Q2 2025 | — |
| Q1 2025 | $193M |
| Q4 2024 | $102M |
APO spent $1.1B buying back its own shares over the past year, up 71% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
APO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -1.1x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
APO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like APO.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
APO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.7 | Neutral |
| Stochastic | 23.4 | Neutral |
APO's weekly RSI is 49 (neutral) and its Stochastic is 23 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
APO PE vs Financial Services Sector
| Metric | APO | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 13x | 224% above |
| PE % | 85 | 63 | 22 pts above |
APO has no meaningful PE right now: it lost money over the past year.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
APO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.5 | 4.2% above |
| 20 week MA | $123.2 | 1.5% below |
| 50 week MA | $126.1 | 3.7% below |
| 100 week MA | $133.4 | 9% below |
| 200 week MA | $116.4 | 4.2% above |
APO has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
APO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.1 | $49.1 | +2.1% |
| 2021 | $49.1 | $74.3 | +51% |
| 2022 | $74.3 | $64.3 | -13% |
| 2023 | $64.3 | $93.2 | +45% |
| 2024 | $93.2 | $170.3 | +83% |
| 2025 | $170.3 | $148.5 | -13% |
| 2026 YTD | $148.5 | $121.4 | -18% |
APO has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.